• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cardlytics Inc.

    5/20/25 4:19:44 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology
    Get the next $CDLX alert in real time by email
    S-8 1 cdlx_2025equityincentivepl.htm S-8 Document
    As filed with the Securities and Exchange Commission on May 20, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    cardlytics_logoa12.jpg
    CARDLYTICS, INC.
    (Exact Name of Registrant as Specified in its Charter)
    675 Ponce de Leon Avenue NE, Suite 4100
    DelawareAtlanta, Georgia 3030826-3039436
    (State or other jurisdiction of
    incorporation or organization)
    (Address of principal executive offices) (Zip code)(I.R.S. Employer
    Identification No.)
    2018 Equity Incentive Plan
    2018 Employee Stock Purchase Plan
    (Full title of the plan)
    Amit Gupta
    Cardlytics, Inc.
    675 Ponce de Leon Avenue NE, Suite 4100
    Atlanta, Georgia 30308
    (Name and address of agent for service)
    (888) 798-5802
    (Telephone number, including area code, of agent for service)
    Copies to:
    Mark Ballantyne
    Trey Reilly
    Cooley LLP
    One Freedom Square
    Reston Town Center
    11951 Freedom Drive
    Reston, VA 20190
    (703) 456-8000
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer ☐  Accelerated filer ☒
    Non-accelerated filer ☐  Smaller reporting company ☐
      Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐




    EXPLANATORY NOTE
    This registration statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering 15,722,908 shares of common stock of Cardlytics, Inc. (the “Registrant”) to be issued pursuant to the Cardlytics, Inc. 2025 Equity Incentive Plan (the “2025 EIP”).
    PART I
    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS
    The information called for by Part I of Form S-8 is omitted from this Registration Statement and included in documents sent or given to participants in the 2025 EIP in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3. Incorporation of Certain Documents by Reference.
    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
    athe Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 12, 2025;
    bthe information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 from the Registrant’s definitive proxy statement on Schedule 14A, as filed with the Commission on April 3, 2025, as amended on April 29, 2025;
    cthe Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which was filed with the Commission on May 7, 2025;
    dthe Registrant’s Current Reports on Form 8-K filed with the Commission on April 28, 2025 and May 20, 2025 ; and
    ethe description of the Registrant’s Common Stock which is contained in the Registrant’s Registration Statement on Form 8-A filed on February 6, 2018 (File No. 001-38386) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.3 to the Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Commission on March 3, 2020.
    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
    Item 4. Description of Securities.
    Not applicable.
    Item 5. Interests of Named Experts and Counsel.
    Not applicable.



    Item 6. Indemnification of Directors and Officers.
    Section 145 of the Delaware General Corporation Law (the “DGCL”) authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.
    Section 102(b)(7) of the DGCL provides that a corporation’s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty, provided that such provision shall not eliminate or limit the liability (i) for any breach of the duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which an improper personal benefit was derived.
    As permitted by the DGCL, the Registrant’s amended and restated certificate of incorporation and amended and restated bylaws provide that: (1) the Registrant may, in its discretion, indemnify its officers, employees and agents as set forth in the DGCL; (2) the Registrant is required, upon satisfaction of certain conditions, to advance all expenses incurred by its directors in connection with certain legal proceedings; (3) the rights conferred in the bylaws are not exclusive; and (4) the Registrant is authorized to enter into indemnification agreements with its directors, officers, employees and agents.
    The Registrant’s policy is to enter into agreements with its directors that require it to indemnify them against expenses, judgments, fines, settlements and other amounts that any such person becomes legally obligated to pay (including with respect to a derivative action) in connection with any proceeding, whether actual or threatened, to which such person may be made a party by reason of the fact that such person is or was a director or officer of the Registrant or any of its affiliates, provided such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, its best interests. These indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder. At present, no litigation or proceeding is pending that involves any of its directors or officers regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.
    The Registrant maintains a directors’ and officers’ liability insurance policy. The policy insures directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses the Registrant for those losses for which it has lawfully indemnified the directors and officers. The policy contains various exclusions.
    Item 7. Exemption from Registration Claimed.
    Not applicable.




    ITEM 8.    EXHIBITS
    Exhibit NumberDescription
    4.1(1)
    Amended and Restated Certificate of Incorporation of the Registrant
    4.2(2)
    Amended and Restated Bylaws of the Registrant
    4.3(3)
    2018 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise, Stock Option Grant Notice. Restricted Stock Unit Notice and Restricted Stock Agreement thereunder.
    4.4(5)
    Specimen stock certificate evidencing shares of Common Stock
    5.1(6)
    Opinion of Cooley LLP
    23.1(6)
    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
    23.2(6)
    Consent of Cooley LLP (included in Exhibit 5.1)
    24.1(6)
    Power of Attorney (included on the signature page of this Form S-8)
    107(6)
    Filing Fee Table
    (1)Previously filed as Exhibit 3.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-222531), filed with the Commission on January 12, 2018, and incorporated by reference herein.
    (2)Previously filed as Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-222531), filed with the Commission on January 12, 2018, and incorporated by reference herein.
    (3)Previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38386), filed with the Commission on May 20, 2025, and incorporated by reference herein.
    (4)Previously filed as Exhibit 4.1 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-222531), filed with the Commission on January 29, 2018, and incorporated by reference herein.
    (5)Filed herewith.

    ITEM 9.    UNDERTAKINGS
    A. The undersigned Registrant hereby undertakes:
    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.
    Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.



    C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Atlanta, State of Georgia, on May 20, 2025.
    CARDLYTICS, INC.
    By:/s/ Amit Gupta
    Amit Gupta
    Chief Executive Officer

    POWER OF ATTORNEY
    Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints Amit Gupta, Nick Lynton and Alexis DeSieno, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.



    SignatureTitleDate
    /s/ Amit GuptaChief Executive Officer and DirectorMay 20, 2025
    Amit Gupta(Principal Executive Officer)
    /s/ Alexis DeSienoChief Financial OfficerMay 20, 2025
    Alexis DeSieno(Principal Financial and Accounting Officer)
    /s/ John Klinck
    Chairperson
    May 20, 2025
    John Klinck
    /s/ Andre FernandezDirectorMay 20, 2025
    Andre Fernandez
    /s/ Jon FrancisDirectorMay 20, 2025
    Jon Francis
    /s/ Srishti GuptaDirectorMay 20, 2025
    Srishti Gupta
    /s/ Scott HillDirectorMay 20, 2025
    Scott Hill
    /s/ Liane HornseyDirectorMay 20, 2025
    Liane Hornsey
    /s/ Alex MishurovDirectorMay 20, 2025
    Alex Mishurov


    Get the next $CDLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDLX

    DatePrice TargetRatingAnalyst
    10/11/2024$4.00In-line
    Evercore ISI
    8/16/2024$5.00Outperform → Market Perform
    Northland Capital
    8/15/2024$4.00 → $3.50Neutral → Underperform
    BofA Securities
    8/8/2024Buy → Hold
    Craig Hallum
    8/8/2024Buy → Hold
    Needham
    8/8/2024$18.00 → $5.00Buy → Hold
    Lake Street
    6/20/2024$11.00Neutral
    BofA Securities
    6/18/2024$14.00Outperform
    Northland Capital
    More analyst ratings

    $CDLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cardlytics Launches Cardlytics Rewards Platform and Expands Publisher Base Beyond Financial Institutions

      Cardlytics Inc. (NASDAQ:CDLX) today announced the general availability of Cardlytics Rewards Platform (CRP), a new solution that provides publishers the opportunity to enhance their customer loyalty programs with card-linked offers. With CRP, a merchant with digital channels and a loyalty program can now become a publisher on the Cardlytics network and offer more value to their customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520125250/en/ Building on its longstanding leadership in financial media, Cardlytics is expanding and diversifying its publisher base to reach engaged consumers in new publisher channels and deli

      5/20/25 9:30:00 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces First Quarter 2025 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2025. "We've made marked progress across our key business pillars, which continue to underpin our journey to 'platformize' Cardlytics and position ourselves as the leading commerce media platform," said Amit Gupta, CEO of Cardlytics. "Our expanding ecosystem, depth and breadth of our data, and ongoing tech investments are strengthening our position and providing differentiated value to our partners and advertisers." "We've built a resilient platform and are making strategic decisions as we look to future-proof our business," said Alexis DeSieno, CFO of Ca

      5/7/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

      Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

      4/30/25 9:00:00 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Financials

    Live finance-specific insights

    See more
    • Cardlytics Announces First Quarter 2025 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2025. "We've made marked progress across our key business pillars, which continue to underpin our journey to 'platformize' Cardlytics and position ourselves as the leading commerce media platform," said Amit Gupta, CEO of Cardlytics. "Our expanding ecosystem, depth and breadth of our data, and ongoing tech investments are strengthening our position and providing differentiated value to our partners and advertisers." "We've built a resilient platform and are making strategic decisions as we look to future-proof our business," said Alexis DeSieno, CFO of Ca

      5/7/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces Timing of Its First Quarter 2025 Earnings Release

      Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the first quarter ending March 31, 2025 will be released on May 7, 2025, after market close. Conference Call Details: When: May 7, 2025 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. Dial-in: Call participants may dial +1 800-549-8228 and use Conference ID: 86123. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party purchase data, that

      4/23/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces Fourth Quarter and Full Year 2024 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2024. "While 2024 was a challenging year for Cardlytics, we nevertheless planted the seeds and refocused our efforts to get back on track for growth this year," said Amit Gupta, CEO of Cardlytics. "We remain grounded in our vision for long-term and sustainable growth. We are focused on strengthening our competitive moat through our efforts to modernize our platform, enhance our product and tech capabilities, and expand our network of partners and advertisers." "In 2025, we are focused on delivering sequential improvements and positive Adjusted EBITDA," said Alexis DeSie

      3/12/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fernandez Andre J

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      5/20/25 4:11:23 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 4 filed by Director Klinck John L. Jr.

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      5/20/25 4:10:21 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 4 filed by Director Francis Jonathan Edward

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      5/20/25 4:09:16 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Cardlytics Inc.

      SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

      7/2/24 7:05:14 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

      SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

      3/29/24 5:05:56 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

      SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

      3/18/24 7:46:57 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on Cardlytics with a new price target

      Evercore ISI initiated coverage of Cardlytics with a rating of In-line and set a new price target of $4.00

      10/11/24 8:36:58 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics downgraded by Northland Capital with a new price target

      Northland Capital downgraded Cardlytics from Outperform to Market Perform and set a new price target of $5.00

      8/16/24 8:54:02 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cardlytics from Neutral to Underperform and set a new price target of $3.50 from $4.00 previously

      8/15/24 7:18:52 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    SEC Filings

    See more
    • SEC Form S-8 filed by Cardlytics Inc.

      S-8 - Cardlytics, Inc. (0001666071) (Filer)

      5/20/25 4:19:44 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Cardlytics, Inc. (0001666071) (Filer)

      5/20/25 4:04:21 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 10-Q filed by Cardlytics Inc.

      10-Q - Cardlytics, Inc. (0001666071) (Filer)

      5/7/25 4:30:52 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Leadership Updates

    Live Leadership Updates

    See more
    • TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

      Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

      4/30/25 9:00:00 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • 23andMe Appoints Three New Independent Directors to Board

      SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

      10/29/24 7:30:00 AM ET
      $ANSS
      $CDLX
      $LSCC
      $ME
      Computer Software: Prepackaged Software
      Technology
      Computer Software: Programming Data Processing
      Semiconductors
    • Cardlytics Appoints Amit Gupta as CEO

      ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced that the Board of Directors has appointed Amit Gupta, Chief Operating Officer and General Manager of Bridg, as its next Chief Executive Officer of Cardlytics, effective August 16, 2024. He will also join the Cardlytics Board of Directors on that date. Mr. Gupta will succeed Karim Temsamani, who is stepping down as Chief Executive Officer and from the Board of Directors to pursue another professional opportunity. "Amit is the right person to lead Cardlytics in its next stage of growth," said Jack Klinck, Chair of the Cardlytics Board. "For the last year and a half, Ami

      8/7/24 4:10:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hill Scott A bought $143,200 worth of shares (40,000 units at $3.58) (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:46:37 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Director Hornsey Liane bought $35,900 worth of shares (10,000 units at $3.59) (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:45:56 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Director Klinck John L. Jr. bought $48,860 worth of shares (14,000 units at $3.49), increasing direct ownership by 26% to 67,593 units (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:39:19 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology